About us
Celsion Corporation is a clinical stage biopharmaceutical company singularly focused on developing its unique heat activated liposomal technology to create more efficacious versions of marketed cancer therapeutics that have the additional benefit of an improved safety profile. Now positioned to address important unmet medical needs, Celsion is gaining momentum in this crucial therapeutic category.
Celsion's technology targets localized cancers with high concentrations of chemotherapeutics through the use of our heat activated lipid technology in combination with FDA approved heating systems, thereby providing more effective treatment.
The market potential for the indications, currently under study by Celsion, suggests excellent valuation appreciation potential for investors in our company's stock. Celsion also believes itself to be an excellent partner for oncology-focused pharmaceutical companies seeking to build their product portfolios with a platform of chemotherapeutics including a unique capability to effectively target solid cancer lesions with high concentration of known anti-cancer agents.
The management team and board of directors of Celsion are committed to building the company into a late stage oncology biotechnology company.